Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma
| Autor: | Leticia Rodriguez, José C. Díaz-Maqueo, Renaldo Guzmán, Agustin Avilés, Alejandra Talavera, Edna L. García |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Pathology Prognostic factor Microgram Gastroenterology Sex Factors Stomach Neoplasms Internal medicine medicine Humans In patient L-Lactate Dehydrogenase business.industry Beta-2 microglobulin Lymphoma Non-Hodgkin Gastric lymphoma Stomach Age Factors Hematology General Medicine Primary Gastric Lymphoma Prognosis medicine.disease Survival Analysis Lymphoma medicine.anatomical_structure Oncology Female beta 2-Microglobulin business |
| Zdroj: | Hematological Oncology. 9:115-121 |
| ISSN: | 1099-1069 0278-0232 |
| Popis: | Sixty-eight previously untreated patients with primary gastric non-Hodgkin's lymphoma (NHL) available for analysis, were entered in a study in which the prognostic significance of serum beta 2 microglobulin levels were evaluated. The serum beta 2 microglobulin was the most significant prognostic factor. Patients with high levels (greater than 3.5 micrograms/mL) had a relapse-free survival (RFS) of 36 months, while the median RFS has not been reached in patients with normal levels (p less than 0.001). The 5-year survival was 80 per cent for patients with normal levels, statistically significant when compared to patients with high levels: 38 per cent (p less than 0.001). Serum beta 2 microglobulin should be included in the initial staging of patients with primary extranodal NHL and patients with high levels should be treated more aggressively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text